PolyPid Net Worth
PolyPid Net Worth Breakdown | PYPD |
PolyPid Net Worth Analysis
PolyPid's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including PolyPid's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of PolyPid's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform PolyPid's net worth analysis. One common approach is to calculate PolyPid's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares PolyPid's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing PolyPid's net worth. This approach calculates the present value of PolyPid's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of PolyPid's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate PolyPid's net worth. This involves comparing PolyPid's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into PolyPid's net worth relative to its peers.
Enterprise Value |
|
To determine if PolyPid is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding PolyPid's net worth research are outlined below:
| PolyPid is way too risky over 90 days horizon | |
| PolyPid appears to be risky and price may revert if volatility continues | |
| PolyPid has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (29.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PolyPid currently holds about 23.78 M in cash with (21.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Roughly 25.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX ... |
PolyPid uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in PolyPid. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PolyPid's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know PolyPid's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PolyPid is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PolyPid backward and forwards among themselves. PolyPid's institutional investor refers to the entity that pools money to purchase PolyPid's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-12-31 | 467 | Ubs Group Ag | 2024-12-31 | 4.0 | Sbi Securities Co Ltd | 2024-12-31 | 1.0 | Golden State Equity Partners | 2024-12-31 | 0.0 | Rosalind Advisors, Inc. | 2024-12-31 | 1 M | Aigh Capital Management, Llc | 2024-12-31 | 827.9 K | Dafna Capital Management Llc | 2024-12-31 | 291.3 K | J. Goldman & Co Lp | 2024-12-31 | 128.5 K | Stonepine Capital Management Llc | 2024-12-31 | 103.7 K | Adar1 Capital Management Llc | 2024-12-31 | 80.1 K | Yelin Lapidot Holdings Management Ltd | 2024-12-31 | 11.2 K |
Follow PolyPid's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.32 M.Market Cap |
|
Project PolyPid's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (2.55) | (2.67) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | 13.09 | 13.75 |
When accessing PolyPid's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures PolyPid's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of PolyPid's profitability and make more informed investment decisions.
Please note, the presentation of PolyPid's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PolyPid's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PolyPid's management manipulating its earnings.
Evaluate PolyPid's management efficiency
PolyPid has return on total asset (ROA) of (0.8631) % which means that it has lost $0.8631 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.3873) %, meaning that it created substantial loss on money invested by shareholders. PolyPid's management efficiency ratios could be used to measure how well PolyPid manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 13.75, whereas Return On Tangible Assets are forecasted to decline to (1.47). At present, PolyPid's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 7 M, whereas Non Currrent Assets Other are forecasted to decline to about 263.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.34) | (1.41) | |
| Tangible Book Value Per Share | (1.34) | (1.41) | |
| Enterprise Value Over EBITDA | (0.51) | (0.54) | |
| Price Book Value Ratio | (2.29) | (2.41) | |
| Enterprise Value Multiple | (0.51) | (0.54) | |
| Price Fair Value | (2.29) | (2.41) | |
| Enterprise Value | 13.2 M | 24.1 M |
Effective leadership at PolyPid drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
PolyPid Corporate Filings
6K | 11th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 26th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
| 21st of January 2025 Other Reports | ViewVerify |
PolyPid Earnings per Share Projection vs Actual
PolyPid Corporate Management
| Ori Warshavsky | Chief US | Profile | |
| Dikla Akselbrad | Chief Officer | Profile | |
| Malka Reichart | Scientific Director | Profile | |
| Rivi Levari | Vice Resource | Profile | |
| Orna Blum | Legal Counsel | Profile | |
| JeanMarc PharmD | Chief Officer | Profile | |
| Tal Vilnai | General Secretary | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PolyPid. If investors know PolyPid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PolyPid listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PolyPid's value and its price as these two are different measures arrived at by different means. Investors typically determine if PolyPid is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PolyPid's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.